HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer

November 26th 2025

T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer

November 22nd 2025

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Phase 3 Data Illuminate Advancing Roles for T-DXd and Combination Approaches in HER2+ Breast Cancer

November 14th 2025

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

November 13th 2025

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

November 13th 2025

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

Five Under 5: Top Oncology Videos for the Week of 11/2

November 9th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Dr Yuan on the Potential Benefit of Upfront T-DXd in HER2+ Breast Cancer With CNS Metastases

November 6th 2025

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

HER2DX Could Aid Chemotherapy Decision-Making in HER2+ Early-Stage Breast Cancer

November 5th 2025

HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.

New ADC Data Underscore Progress and Highlight Challenges in HER2+ Breast Cancer and TNBC Management

November 2nd 2025

In a recent Peer Exchange, breast cancer experts discussed updates from ESMO 2025, including practice-informing data with antibody-drug conjugates.

Dr Yuan on the DEMETHER Trial of Induction T-DXd Plus HP Maintenance in HER2+ Breast Cancer

October 30th 2025

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

October 27th 2025

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

October 23rd 2025

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Dr Tarantino on De-Escalated THP With/Without Carboplatin in HER2+ Breast Cancer

October 23rd 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer

October 23rd 2025

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.